Global Endocrine Testing Market Players
- Roche Diagnostics
- Abbott Diagnostics
- Siemens Healthineers
- Beckman Coulter
- Ortho Clinical Diagnostics
- DiaSorin
- Thermo Fisher Scientific
- Agilent Technologies
- Waters Corporation
- Bio-Rad Laboratories
- Tosoh Bioscience
- Snibe / Mindray
- Fujirebio
- QuidelOrtho
- LabCorp
- Quest Diagnostics
- ARUP Laboratories / Mayo Clinic Labs
- Eurofins / Synlab
- Abbott / Roche POC divisions
Market Growth
The global endocrine testing market size is calculated at USD 2.99 billion in 2024, grew to USD 3.24 billion in 2025, and is projected to reach around USD 6.75 billion by 2034. The market is expanding at a CAGR of 8.54% between 2025 and 2034.
What are the Market Trends?
Investment & Funding
In May 2025, Hormona, a women healthcare startup based in London, raised $6.7 million in a seed funding round to introduce its hormone tests. The company main offering is a hormone monitoring app that lets users record their overall health, symptoms, and menstrual cycles. The app finds trends and provides information about changes in hormone-related health using user-inputted data and algorithmic analysis.
Increase Clinical Uptake of Diagnostics & Market Expansion Opportunity
In August 2025, Merck, a leading science and technology company, welcomed new expert guidelines that will standardize the tests used in Australia and New Zealand to diagnose and treat endocrine disorders in children.
Adoption of Inorganic Growth Strategies
In July 2025, The Norman Parathyroid Center at the Hospital for Endocrine Surgery is pleased to announce a nationwide partnership with Any Lab Test Now in observance of Parathyroid Awareness Month. This partnership will expand access to diagnostic testing for hyperparathyroidism, a prevalent but underdiagnosed endocrine disorder that primarily affects women over 50.
Endocrine Testing Market Value Chain Analysis
Research & Development (R&D)
- Target Identification: Identify hormones or endocrine biomarkers associated with specific disorders.
- Assay Development: Develop sensitive and specific diagnostic assays for target hormones.
- Technology Optimization: Refine testing methods using automated immunoassays, mass spectrometry, or AI-based analysis.
- Prototype Validation: Conduct internal validation of assays under controlled laboratory conditions.
- Preclinical Research: Test accuracy, reproducibility, and stability of assays in vitro or using biological samples.
- Organizations: Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Qiagen, Harvard Medical School, and the University of Tokyo, among others
Clinical Trials & Regulatory Approvals
- Pilot Studies: Conduct small-scale trials to assess assay performance on patient samples.
- Large-Scale Clinical Trials: Evaluate safety, efficacy, and diagnostic accuracy in diverse populations.
- Regulatory Submission: Submit data to regulatory authorities (e.g., FDA, EMA) for clearance or approval.
- Compliance Verification: Ensure adherence to quality standards, good laboratory practice (GLP), and ISO certifications.
- Market Authorization: Obtain approvals for commercialization in specific regions.
- Organizations: Parexel, PPD (Pharmaceutical Product Development), U.S. FDA, EMA (European Medicines Agency), CDSCO (Central Drugs Standard Control Organization, India), and Hospitals & Specialty Labs
Patient Support & Services
- Sample Collection & Testing: Collect patient samples at hospitals, labs, or home collection centers.
- Reporting & Interpretation: Deliver test results with clinical interpretation and alerts for abnormal values.
- Follow-Up Services: Provide counseling, repeat testing, and monitoring recommendations for patients.
- Digital Health Integration: Enable patient access to results via apps, portals, and remote monitoring devices.
- Awareness & Education: Conduct patient education campaigns about endocrine health and preventive testing.
- Organizations: LabCorp, Quest Diagnostics, Babylon Health, Teladoc Health, American Diabetes Association (ADA), European Thyroid Association (ETA), and Pharmacies & Health Clinics
Latest Announcement by Industry Leaders
In January 2025, the U.S. Food and Drug Administration announced that EUROIMMUN (part of Revvity) achieved both FDA 510(k) clearance and CE marking for a chemiluminescence-based immunoassay that measures free testosterone, delivering results in under 48 minutes.
Recent Developments in the Endocrine Testing Market
- In June 2025, IDEXX Laboratories, Inc., a leader in pet healthcare innovation worldwide, revealed the launch of the Catalyst Cortisol Test, which measures quantitative cortisol concentrations in real time to aid in the diagnosis and treatment of Cushing syndrome in dogs as well as Addison disease. The third menu addition to the Catalyst platform in less than a year is IDEXX Catalyst cortisol test, which enhances the diagnostic tools that veterinary practices can use at the point-of-care.
- In March 2025, Level Zero Health, a London-based HealthTech startup, raised US $8.4 million in pre-seed funding to develop DNA-based sensor technology aimed at enabling remote and continuous hormone monitoring.
- In January 2025, Eli Health, introduced at CES in January 2025 as an at-home hormone-testing system using saliva plus smartphone analysis. It initially measures cortisol and progesterone, with beta access rolling out soon in the US and Canada, full release planned later in the year. Estimated pricing starts at about US $8/month with a year-long commitment. Future expansions are planned for testosterone and estradiol tests.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
